People are mixing supplements, herbs and over-the-counter medications and prescription drugs to cure themselves of ills, unaware that they could be making themselves sicker, says George Grossberg, M.D., director of the division of geriatric psychiatry at Saint Louis University.
Diabetes and high blood pressure, two conditions rooted in genetics and environmental surroundings, play a much greater role than race alone in determining who is mostly likely to develop heart failure, according to the latest study from cardiologists at Johns Hopkins. Each year, nearly 300,000 Americans die from heart failure.
In an era of increasing death and illness from heart and blood vessel disease — which also can impair kidney function — Mayo Clinic researchers have designed two promising new cardiovascular treatment approaches.
Researchers today reported that an investigational anti-hypertensive therapy may perform better in controlling blood pressure than standard treatments for patients undergoing heart surgery, during a presentation at the American College of Cardiology?s 56th Annual Scientific Session.
Chest pain due to a shortage of blood in the heart, known as angina, is a condition that affects millions of Americans. The most recently approved new pharmaceutical approach to treat chronic angina is a novel drug called ranolazine, which was approved in 2006 for use as second line therapy in patients who continue to experience angina despite treatment with another class of anti-anginal medication.
A combination of two medicines that act against the effects of the enzyme renin are more effective in lowering blood pressure than either of the medicines alone, according to a study presented today at the American College of Cardiology?s 56th Annual Scientific Session.
High blood pressure is the most common chronic medical condition in the United States, and the most common identifiable cause is narrowing of a kidney artery, called renal artery stenosis.
Giving up smoking can reduce the risk of dying from the disease by up to 70 percent, new research published in the American Journal of Epidemiology this week shows.
Cleveland Clinic researchers report that the drug torcetrapib, despite raising high density lipoprotein cholesterol (HDL) or the “good” cholesterol by more than 60%, did not slow the progression of plaque buildup in the coronary arteries as measured using an ultrasound probe.
An international study using ultrasound technology has found that the most potent cholesterol-lowering drug is also effective at halting early changes in the blood vessels that can lead to atherosclerosis.